US FDA probatus est gilteritinib ( Xospata ) Ad curatio de aegris cum adultus FLT3 mutationem, laxantur aut positivae durum acutus myeloid leukemia ( AML ).
When used with gilteritinib , it also awards companion diagnostic genetic testing technology. The LeukoStrat CDx FLT3 mutation detection method developed by Invivoscribe Technologies , Inc. is used to detect FLT3 mutations in AML patients .
'De XXV% -25% de aegris cum AML FLT30 mutatur genes, "FDA medicamentis Administration emendator Centrum pro FDA de Haematologia et Oncology et Oncology productum agendi emendator Centrum Pazdur Richard, MD, and Research, in denuntiatione dixit. "Haec consociata cum mutationes cancer sunt, praecipue in irascibili et altiorem periculo coetus. '
Pazdur adiecit gilteritinib probatus est primum medicatum utendum est MONOTHERAPY AML patientes in nationibus.
FLT3 is the most frequently mutated gene identified in AML ,and FLT3 internal tandem repeat mutations are associated with high relapse rates, short remissions, and poor survival outcomes. Gilteritinib is a highly selective FLT3 tyrosine kinase inhibitor that has been shown to have activity against FLT3 ITD mutations, and also inhibits FLT3 D835 mutations that can confer clinical resistance to other FLT3 inhibitors .
CCLII aegris Et ascribantur ex Iudæis in primo ostendit quod tempus 252/1 iudicium XLIX% de aegris cum portu, vel praefracti AML FLT2 mutationes et respondit ad gilteritinib. Mediana salvos esse hos participantium magis quam VII menses. Non solum XII% de aegris FLT49 responderit gilteritinib mutationes taceam, quantum ad id quod potest esse sicut electionem selectivam Matrix FLT3 mutant.
Et secundum quod probat PRAEFECTUS CLASSIS notitia de studio, a randomized iudicium III tempus in quo CXXXVIII adulta patientibus positivum FLT3- portu / durum AML accepit CXX mg cotidie gefitinib oris. Huius generis causarum, XXI% de aegris effectum plenarie remissionis ex parte aut ex toto remittuntur hematological convaluisset. PRAEFECTUS CLASSIS ipsa iudicium et adhuc profectum, et salvos Responsio et altiore notitia expectata published in proximum annum.
https://www.medscape.com/viewarticle/905713
